SYNDAX PHARMACEU.DL-,0001

Syndax reports that Revuforj is achieving an annualized revenue well over $200 million in its second year on the market and generated $55 million in the last quarter; market share is around 85% in relapsed/refractory AML with KMT2A and NPM1 mutations. Two approval-relevant phase III first-line studies (EVOLVE-2 for unfit patients, REVEAL for fit patients) are progressing well, while the company plans further label expansions and combination tests. In parallel, Syndax is advancing development of Niktimvo in IPF and cGvHD and new programs in lung cancer and myelofibrosis, with initial clinical starts for two projects planned for 2027. » Mere på de.investing.com

Syndax reported Q2 revenue of $73 million and a loss of $0.55 per share, missing both revenue and earnings expectations. Revenue grew 92% year‑over‑year, driven by Revuforj (net revenue $54.7 million) and Niktimvo (collaboration revenue $18.1 million), and management expects projected annual revenues for both products to be well over $200 million. The company ended the quarter with $575 million in cash, reiterated its operating cost guidance for 2026, and cited several clinical data catalysts for the second half of the year; the stock fell after hours following the missed metrics. » Mere på de.investing.com

Guggenheim cut its price target for Syndax Pharmaceuticals to $31 from $34 but kept a Buy rating after revising acute myeloid leukemia market assumptions and factoring recent commercial updates. Syndax published Phase 1/2 SAVE results showing an overall response rate of 88% and a 71% composite complete remission rate for a Revuforj, decitabine/cedazuridine and venetoclax oral regimen, with activity across genetic subgroups and a generally manageable safety profile. The analyst also considered Kura Oncology developments when adjusting Syndax's valuation; Syndax remains a commercial-stage company focused on hematologic malignancies. » Mere på finance.yahoo.com